Metabolic disorders are commonly investigated using knockout and transgenic mouse models on the C57BL/6N genetic background due to its genetic susceptibility to the deleterious metabolic effects of high-fat diet (HFD). There is growing awareness of the need to consider sex in disease progression, but limited attention has been paid to sexual dimorphism in mouse models and its impact in metabolic phenotypes. We assessed the effect of HFD and the impact of sex on metabolic variables in this strain.
We generated a reference data set encompassing glucose tolerance, body composition and plasma chemistry data from 586 C57BL/6N mice fed a standard chow and 733 fed a HFD collected as part of a high-throughput phenotyping pipeline. Linear mixed model regression analysis was used in a dual analysis to assess the effect of HFD as an absolute change in phenotype, but also as a relative change accounting for the potential confounding effect of body weight.
HFD had a significant impact on all variables tested with an average absolute effect size of 29%. For the majority of variables (78%), the treatment effect was modified by sex and this was dominated by male-specific or a male stronger effect. On average, there was a 13.2% difference in the effect size between the male and female mice for sexually dimorphic variables. HFD led to a significant body weight phenotype (24% increase), which acts as a confounding effect on the other analysed variables. For 79% of the variables, body weight was found to be a significant source of variation, but even after accounting for this confounding effect, similar HFD-induced phenotypic changes were found to when not accounting for weight.
HFD and sex are powerful modifiers of metabolic parameters in C57BL/6N mice. We also demonstrate the value of considering body size as a covariate to obtain a richer understanding of metabolic phenotypes.
The development of transgenic and knockout mouse technologies has facilitated the production of in vivo models that have greatly enhanced our understanding of disease mechanisms and have become commonplace in medical research. The C57BL/6N (B6N) background strain is becoming the standard background for genetic manipulation of the mouse genome.1, 2 Similar to the well-known C57BL/6J strain, B6N mice are susceptible to high-fat diet (HFD)-induced conditions including body weight gain, increased adipose mass, liver lipid infiltration and alterations in biochemical variables.1, 3 Because of the increasing adoption of this background for genetically modified and non-genetically modified studies in mice, baseline data from C57BL/6N mice are important for being able to examine its performance between laboratories and to justify the use of this strain when designing experimental procedures.
Historically, research into biological processes has overlooked the impact of sex. Systematic reviews of animal research studies identified a vast over-representation of male mice, and where both sexes were studied, two-thirds of the time, the results were not statistically analysed with regard to the effect of sex.4, 5, 6 The observations that many human diseases exhibit some sex differences in prevalence,7 course, severity8 and drug reaction9 has led to a growing concern over the sex imbalance and lack of generalisability of results in biomedical research.10 Sexual dimorphism can be defined as the difference in a particular characteristic between sexes in either standard conditions, or in response to a stimulus. Assessment of sexual dimorphism under standard or non-challenged conditions can be thought of as binary (for example, the change in sex leads to the feature being present or absent; or if continuous trait larger or smaller). In contrast, assessing sexually dimorphic responses to stimuli is more complex with multiple potential outcomes: both sexes show similar responses; only one sex is affected by the stimulus; both sexes are affected to differing degrees; and sexes have opposite responses to a stimulus. Despite being a well-known phenomenon, to date, we have only identified a few publications that explicitly looked at the role of sex in the response to HFD in mice.11, 12, 13, 14
Typically with metabolic studies, the treatment will be associated with a weight change. However, body weight is known to be a powerful co-variable and this correlation can lead to an association that is true but potentially biologically misleading. The importance of considering weight in interpreting phenotypes, and doing so correctly via regression, has been raised previously.15, 16, 17 Therefore, a dual analysis approach has been proposed, first assessing the treatment impact on the absolute phenotype and then assessing the treatment impact on the phenotype relative to body weight.18 This dual analysis strategy will give a more detailed understanding of the impact of the treatment.
The International Mouse Phenotyping Consortium (IMPC19) aims to phenotype knockouts for all protein coding genes in the mouse genome, and provide the lines and data to form an open resource to the community. These high-throughput phenotyping pipelines are designed to systematically test mice through a number of assays in a standardised, unbiased manner to explore a range of vertebrate biology. To provide a baseline for statistical analysis of mutant phenotypes, the pipelines typically phenotype control mice matched for age, sex and strain every week. Cumulatively, this wild-type data set provides a substantial amount of information on systematically phenotyped mice in numbers that are unusual in hypothesis-driven mouse phenotyping. These data can provide insights into physiology otherwise undetected under normal laboratory conditions. The Wellcome Trust Sanger Institute Mouse Genetics Project (MGP) has been running a high-throughput phenotyping pipeline since 2006.20 The programme consists of standardised and validated screens, but due to changing objectives, the diet changed from a HFD to a breeders chow, giving large quantities of B6N control data under the two conditions.
In this paper, we explore the B6N data sets of the MGP to answer three questions. First, we capture the typical metabolic profile for B6N mice under standard chow diet and HFD conditions, using linear mixed model regression to fit an absolute change model (ACM) to derive the absolute changes generated by the HFD. Then, we fitted a weight-adjusted model (WAM) to assess the influence of HFD on metabolic variables after adjusting for a potential confounding effect of body weight. Then in both models, we asked whether there are sexually dimorphic differences in the metabolic response to a HFD. As a resource to the community, we provide the data and scripts.21
Animals, housing and husbandry
B6N mice were phenotyped in weekly batches of seven males and females as part of the standardised pipelines from the MGP at Wellcome Trust Sanger Institute. Mice phenotyped by the Mouse GP pipeline (January 2011–February 2012) were given a HFD from 4 weeks of age (Western RD, 829100, 21.4% crude fat content, 42% kcal as fat, ~0.2% cholesterol, Special Diet Services, Witham, UK).20 Mice phenotyped by the MGP Select pipeline (February 2012–February 2013) were given a breeders chow (Mouse Breeder Diet 5021, 9% crude fat content, 21% kcal as fat, 0.276 p.p.m. cholesterol, Labdiet, London, UK) from weaning. Diet compositions are given in Table 1. All mice were given water and diet ad libitum, unless otherwise stated.
The care and use of mice in the Wellcome Trust Sanger Institute study was carried out in accordance with UK Home Office regulations, UK Animals (Scientific Procedures) Act of 1986 under two UK Home Office licences that approved this work, which were reviewed regularly by the Wellcome Trust Sanger Institute Animal Welfare and Ethical Review Body.
Data from the following screens were included for analysis in this manuscript: overnight fast followed by intraperitoneal glucose tolerance test (ipGTT) at 13 weeks of age; dual-energy X-ray absorptiometry (DEXA) at 14 weeks of age; and clinical chemistry at 16 weeks of age. The two phenotyping pipelines were identical with the exception that the Mouse GP has four additional screens (hair phenotyping, open field, hot plate and stress-induced hypothermia tests). The analysis presented here assumes that the omission of these screens in the MGP Select pipeline does not impact the outcomes of the ipGTT, DEXA and clinical chemistry screens. The final data set contained 296 female and 290 male mice from MGP Select (breeders chow), and 363 female and 370 male mice from Mouse GP (HFD). The experiment was not replicated, rather the analyses incorporates data from a large time period encompassing many animals and litters.
DEXA was performed alongside the tests for auditory brainstem response and whole body, high-resolution digital X-ray. Mice were anaesthetised with ketamine hydrochloride. Nose to tail base length measurements were performed using a ruler with 1 mm graduations prior to DEXA measurement. Body composition parameters were measured using a PIXImus densitometer in combination with Lunar PIXImus2 2.1 software (GE Lunar, Madison, WI, USA).
Intraperitoneal glucose tolerance test: mice were single housed and fasted overnight (typically 16 h). A fasting (T0) blood sample from the tail tip was directly taken (Accu-chek Aviva, Roche, Indianapolis, IN, USA). Mice were then injected with 2 g kg−1 glucose intraperitoneally. Further blood samples were taken at 15 (T15), 30 (T30), 60 (T60) and 120 (T120) min post glucose injection. Area under the curve was calculated using the trapezoid method, where glucose at T0 was used as the baseline value for the mouse. Glucose clearance rate in mm min−1 was calculated by the formula (glucose at T120–glucose at T30)/90.
Clinical chemistry: blood was collected from animals in the random-fed state between 0830 and 1030. Mice were anesthetised using 100 mg kg−1 Ketamine and 10 mg kg−1 Xylazine, and blood was collected into heparinised pediatric tubes (Kabe Labortechnik GmbH, Numbrecht, Germany) using the retro-orbital route, followed by heart removal. Heparinised whole-blood samples were centrifuged at 5000 r.c.f. for 10 min at 4 °C, and the separated plasma analysed using an Olympus AU400 (High Wycombe, UK).
Further information about housing and husbandry, experimental procedures and pipeline quality control performed in the screen can be found in the Supplementary Material.
Statistical and bioinformatics analysis
The individual mouse was considered the experimental unit within the studies. An iterative top down mixed modelling strategy was performed as described in Karp et al.22 using PhenStat version 2.3.2,23 an R package freely available from Bioconductor.24 The package’s mixed model framework was used inputting diet as the genotype variable. The ACM (Equation 1) was obtained by setting the argument equation to ‘withoutWeight’ and the WAM (Equation 2) by setting the argument to ‘withWeight’.
The reference group was the breeders chow (MGP Select) female mice, and hence model estimates for ‘Sex’ are for the impact of being male and for ‘Diet’ the impact of the HFD. The covariance structure for the residual is assessed, and if significant (P<0.05), then the model uses a heterogeneous model to account for the variance depending on diet. PhenStat uses a model optimisation strategy, and therefore, if weight as a covariate is not found to be a significant source of variation, it is dropped from the modelling process, and in effect, the WAM is equivalent to the ACM. The appropriateness of the models was assessed by visual inspection of graphic tools provided with PhenStat. In Equation 2, where weight is included as a covariate, the model adjusts for this variable by estimating the linear relationship between the covariate and the variable of interest, and as such makes two assumptions. First, that there is a linear relationship between the confounding variable and the variable of interest, and second, the assumption that a common linear relationship exists across treatment groups (homogeneity of regression slope). These assumptions can be assessed by plotting the confounding variable (body weight) against the outcome (phenotypic measure) and comparing the gradients on regression lines fitted for each experimental condition (pipeline). This was inspected for each variable, and this assumption was found to not be valid for five variables (log(alanine transaminase), log(aspartate aminotransferase), alkaline phosphatase, low-density lipoprotein cholesterol and free cholesterol). In these situations, the WAM was not appropriate. For these variables, we explored the data and the relationship with weight using a model that allowed for an interaction, and as the relationship was complex and the effect of diet could not be separated from weight, no weight-adjusted analysis was completed.
The appropriateness of the model output was also assessed by inspection of normal quantile–quantile plots of the residuals, a box plot that assessed the distribution of the residuals with batch by diet, and a plot that compares the residuals against predicted for each diet. From this analysis, four variables (insulin, creatine kinase, aspartate aminotransferase and alanine transaminase) were found to have issues with the ‘normality of residual’ assumption when fitted with Equation 1 and Equation 2. A log10 transformation addressed this issue.
Percentage change was calculated to allow comparison of the diet effect for each sex across variables by taking the estimated coefficient from the regression analysis and dividing it by the average signal seen for that variable. Multiple testing was managed by controlling the family-wise error rate to 5% using the Holm method.25
Data access and code availability
As a reference data set set for these animal models, we have made the data freely available via Zenodo.21 As a reproducible analysis, we also provide the scripts and output data that generated the results presented within the manuscript.21
The effect of HFD, independent of sex and body weight
First, we investigated the impact of the HFD, assessing for absolute changes in phenotypes independent of sex and body weight differences by utilising the ACM (Table 2, Supplementary Table 1). Body weight on average increased by 24% at the three time points studied. For the other 38 variables examined, all were statistical significantly different. With large group size of mice contributing to the overall power to detect change of small effect size, the effect size for a given parameter could be small. The average largest effect seen across the two sexes for each variable was 29% with a range of 1.5–135% (s.d.: 28.1%). If we arbitrarily select a 5% threshold for biologically significance, then 87% (33/38) of the variables were significantly affected by diet. As expected for a HFD, glucose tolerance decreased, the body composition was primarily affected by a substantial increase in fat mass, and in plasma chemistry, most variables related to lipid and protein metabolism were increased, however, plasma triglycerides, creatinine and urea were decreased.
HFD affects phenotypes in a sexually dimorphic manner
Sex was found to be a statistically significant modifier of the effect of diet for the majority of traits (78%, 32/41) (Figures 1 and 2; Supplementary Table 1). By looking at the model estimates, the change observed could be classified according to outcome.23 For 22% (9/41) of variables, the effect was equal across the two sexes. For those classified as having a sexually dimorphic phenotype, the effect was dominated by male-specific/more pronounced male classifications (63.4%, 26/41) with the remainder being classified as female-specific/more pronounced female (14.6%, 6/41) (Figure 2). On average, for those variables classed as sexually dimorphic, there was a 13.2% difference in the effect size between the sexes (range: 0.42%–71.2%).
Glucose control, examined by ipGTT (Figure 1a), was affected in a sexually dimorphic manner. Male mice on HFD showed worsened blood glucose levels at almost all time points during the ipGTT compared to the female HFD-fed mice. Also the glucose clearance rate was only altered in the HFD males, while the HFD female had a glucose clearance rate that was comparable to the chow-fed females (Figure 1b). In terms of body composition, the major effect of HFD was elevated fat mass (Figure 2a), although sexually dimorphic effects were also noted for this and for bone parameters, with males being more affected than females. Regarding clinical chemistry, insulin levels were higher in male HFD mice compared to female HFD mice (Figure 2b), as were liver enzymes related to steatohepatitis, aspartate aminotransferase and alanine transaminase. In addition, HFD males also had worsened plasma lipid profiles, with higher cholesterol levels compared to the HFD females (Figure 2c).
Inclusion of body weight as a covariate impacts the outcomes of metabolic phenotype analysis
We then assessed the relationship between the variables and body weight for the two diets. Visually, inspection of the relationship between body weight and diet, found five variables for which the relationship with weight depended on the diet (log(aspartate aminotransferase), alkaline phosphatase, free cholesterol, log(alanine transaminase) and low-density lipoprotein cholesterol). These variables positively correlated with body weight in HFD-fed mice, but not for the breeders chow-fed mice, despite overlap in the body weight ranges for these diets (Figure 3). This demonstrates selective, weight-independent effects of HFD on important and commonly measured physiological parameters. In addition, a positively correlated relationship was seen between body weight and both lean mass and fat mass, and the relationship was independent of diet (Supplementary Figure 1). Therefore, for the five variables, the differing relationship with weight is not due to an alternative relationship with lean or fat mass (Supplementary Figure 2). Therefore, as the effect of body size could not be separated from the effect of diet, these five variables were not carried forward for further analysis.
For the remaining variables, we assessed the effect of diet on the phenotype after adjusting for the confounding relationship with weight using WAM. This determined the body-weight-adjusted relative change in phenotype. With the model optimisation strategy implemented, weight as a covariate would only be included if it was a significant source of variation (likelihood ratio test P<0.05) and was included for 79% (26/33) of the variables.
Of the 33 variables assessed with the WAM model, the effect of HFD was significant in 93.9% (31/33), and of those that were significant, the average largest effect seen across the two sexes for these variables was 18.2% (range: 1.9–58.9%, s.d.: 15.7%). Including an additional arbitrary biological filter of 5% leads to 72.7% (24/33) of variables being classed as significantly different between the breeder’s chow diet and HFD. In addition, of those classed as statistically significant, sex was found to be a modifier of the effect of diet for the majority of traits (81.8%, 27/33) (Figure 4). For just 12% (4/33), the effect was classed as ‘both sexes equally’ as there was no evidence of an interaction between sex and diet, while for those identified as having a sexually dimorphic phenotype, the effect was dominated by male-specific/male stronger classifications (48.4%, 16/33) compared to female-specific/female stronger (30.3%, 10/33). One variable, DEXA bone area, was found to be sexually dimorphic, but with the direction of effect in opposite directions for each sex (Figure 4). On average, for those classed as sexually dimorphic, there was a 9.5% difference in the effect between the sexes (range: 0.42–29.4%).
Our analysis demonstrates that after accounting for body weight differences, the majority of variables were still significantly different between the breeder’s chow diet and HFD. However, the average maximum effect size across the sexes was reduced (ACM: 29%, WAM: 18.2%). In addition, for sexually dimorphic variables, the inclusion of body weight as a covariate reduced the size of the difference seen between the sexes (ACM: 13.2%, WAM: 9.5).
We have used data generated from our high-throughput phenotyping pipeline to develop a core resource for research centred on the B6N mouse. In total, we use data on 41 metabolic-related variables from 1319 mice to produce a highly sensitive assessment of the impact of diet and sex on these variables. This extensive reference data set finds that the HFD has a wide-ranging impact on the metabolic variables, both when assessed for an absolute phenotypic difference and in the relative phenotypic effect where body weight is accounted for. While a number of papers have previously considered the metabolic profile of B6N mice,1, 26, 27 to date, little attention has considered the role of sex in the phenotype, particularly in conjunction with HFD.
Our analysis finds that sex is a significant modifier of the impact of HFD (78% of variables with the ACM) and is dominated by the males being affected to a greater degree than the females. The finding that sex is a significant modifier, supports the call4, 5, 10, 28 to always consider sex when designing and analysing in vivo studies. Indeed, sexual dimorphism in metabolic disorders such as obesity29 and atherosclerosis30 are well described and biologically important element of understanding their aetiologies. However, most in vivo studies focus on male mice.4 Historically, females were thought to have greater variability due to the oestrogen cycle, this however has been largely disproven.31, 32 In addition, previous studies have noted that the development of obesity and hyperglycaemia is strain-dependent and dependent on sex.33, 34 The extent of sexual dimorphism seen in this data set, combined with previous examples of phenotypic outcomes depending on sex, demonstrate the importance of assessing the role of sex when conducting research to understand disease progression, severity and treatment.
In general, many of the global findings on weight and glucose control for the effect of HFD on C57BL/6N observed were similar to those previously published.35, 36, 37 Our comprehensive analysis also identifies additional variables that are affected by HFD in the C57BL/6N background. The challenge with using mouse models for complex diseases, such as obesity and the metabolic syndrome, is that certain phenotypic outcomes may not fully recapitulate all aspects of the human disease. For example, we find that plasma iron levels are reduced in C57BL/6N HFD-fed mice, which matches the general observation that obesity corresponds with iron deficiency in humans.38 However, markers of elevated iron stores such as hyperferritinemia occur in a subset of metabolic syndrome patients and has been termed ‘dysmetabolic iron overload syndrome’.39 Similarly, bilirubin levels are inversely correlated with prevalence of type 2 diabetes in humans,40 and mouse models of insulin resistance are protected by haem oxygenase-induced production of bilirubin.41 However, increased haem oxygenase-1 expression is associated with insulin resistance and loss of haem oxygenase-1 also appears to be protective against metabolic disorders in mouse.42 In our analysis, bilirubin levels are elevated in HFD-fed mice, suggesting that the haem oxygenase-bilirubin pathway may be enhanced, thereby altering the baseline that the effect of interventions must be measured from. Our data therefore suggest that the design and interpretation of studies using HFD-fed mice to model human diseases should be careful evaluated.
In addition to the high prevalence of sexual dimorphism, our analysis found that with diet impacted most variables both when assessing the phenotypic change in absolute and relative terms. The use of a body weight correction by regression has been proposed for certain metabolic assays, for example, indirect calorimetry measurements of energy expenditure15 or body composition measures.43 A dual analysis, assessing both absolute and relative phenotypic changes, gives a richer understanding of the treatment. Bone mineral density (BMD), is one variable where published analysis has frequently considered the animal size as a co-variable. In humans, obesity is thought to increase BMD by mechanical loading, but also increases fracture risk.44 However, other studies point to an inverse relationship with BMD.45, 46 These conflicting observations highlight the complexity of the relationship, an observation that is also seen in the mouse literature. For example Li et al.,47 studying multiple inbred mouse strains, concluded that the relationship between BMD and body composition, particularly fat mass, is dependent on the diet used. They also reported that while sex had no net effect on BMD, once body weight is taken into account, females have a higher BMD than males. In comparison, using the ACM on our B6N mouse data, we find that HFD affects bone density in a sexually dimorphic manner, so that males have a greater response than females. In comparison, using the WAM to take body weight into account, we find the relative effect of HFD is an unchanged BMD in males but lowered BMD in females. As noted by Li et al. and others,47, 48, 49 the relationships between body composition, BMD, genetics, diet and environment are complex, and the experimental design, the model system and the specific variables and co-variables measured will play a significant part in the outcome from dietary interventions.
In summary, we have produced a reference data set for normal and HFD-fed C57BL6/N mice from a standardised phenotyping pipeline. We demonstrated that sexual dimorphism exists in the response to the diet in a large range of common metabolic variables, and suggest that analysis examining the effect of sex and body weight on phenotypes should be encouraged.
This research was supported by the Wellcome Trust via grant WT098051. We thank the Sanger Institute’s Research Support Facility, MGP and Mouse Informatics Group who collected and freely disseminated the phenotyping data used in this manuscript. We thank Sam Virtue (Institute of Metabolic Science, Cambridge, UK) for valuable discussions about this data set.
About this article
Rights and permissions
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
Supplementary Information accompanies this paper on the Nutrition & Diabetes website (http://www.nature.com/nutd)